eagle-i University of Hawaii at ManoaUniversity of Hawaii at Manoa
See it in Search
This page is a preview of the following resource. Continue onto eagle-i search using the button on the right to see the full record.

Evaluate novel agents with intensive multi-agent interval compressed reaction for high-risk rhabdomyosarcoma

eagle-i ID


Resource Type

  1. Clinical trial


  1. Intervention
  2. Intervention
  3. Intervention
  4. Additional Topic(s)
    Antineoplastic combined chemotherapy
  5. Resource Description
    This trial evaluates the addition of novel therapeutic agents to the intensive chemotherapy used in the previous COG trial for metastatic rhabdomyosarcoma. As in the previous trial, patients enrolled in this study will be treated with an intensified chemotherapy regimen. This study will assess the feasibility of adding new agents to the chemotherapy backbone. Patients in Pilot 1 will have cixutumumab added to their weekly chemotherapy. Patients in Pilot 2 will have temozolomide added to their vincristine/irinotecan cycles. Patients in Pilot 3 will receive both cixutumumab and temozolomide with the chemotherapy.
  6. Contact
    Berenberg, Jeffrey
  7. PI
    Wilkinson, Robert, M.D.
  8. Topic
  9. Study Population
    Patients must have newly diagnosed (within 42 days of enrollment), biopsy-confirmed metastatic rhabdomyosarcoma (RMS) or ectomesenchymoma, including the following: Embryonal RMS (for patients 10 to 49 years of age) ; Alveolar RMS or ectomesenchymoma (for patients under 50 years of age)
  10. Funded by
    Children's Oncology Group
  11. Phase
    Phase 0 clinical trial
  12. Performed by
    Clinical Protocol & Data Management Shared Resource
Provenance Metadata About This Resource Record
Copyright © 2016 by the President and Fellows of Harvard College
The eagle-i Consortium is supported by NIH Grant #5U24RR029825-02 / Copyright 2016